Edgar Bronfman submits $4.3 billion bid for Redstone's National Amusements, Paramount stake, WSJ reports-February 2024-www.financetom.com

Edgar Bronfman submits $4.3 billion bid for Redstone's National Amusements, Paramount stake, WSJ reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Edgar Bronfman submits $4.3 billion bid for Redstone's National Amusements, Paramount stake, WSJ reports

Aug 19, 2024 8:06 PM

(Reuters) - Media executive Edgar Bronfman made a $4.3 billion bid for Shari Redstone's National Amusements and a minority stake in Paramount Global ( PARAA ), the Wall Street Journal reported on Monday, citing people familiar with the matter.

Previous page： Fti Consulting Insider Sold Shares Worth $9,394,746, According to a Recent SEC Filing Next page： Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Fti Consulting Insider Sold Shares Worth $9,394,746, According to a Recent SEC Filing

May 3, 2024

04:07 PM EDT, 05/03/2024 (MT Newswires) -- Steven Henry Gunby, Director, President & CEO, on May 01, 2024, sold 44,113 shares in Fti Consulting ( FCN ) for $9,394,746. Following the Form 4 filing with the SEC, Gunby has control over a total of 311,297 shares of the company, with 311,297 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/887936/000088793624000069/xslF345X03/wk-form4_1714766625.xml Price: 215.14, Change:...

Johnson & Johnson Says Erleada Combination Therapy Achieves 100% BCR-Free Rate

May 3, 2024

04:07 PM EDT, 05/03/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Friday that its latest Phase 2 Apa-RP study on Erleada and ADT combination therapy in post-radical prostatectomy patients with high-risk localized prostate cancer showed a 100% biochemical recurrence-free rate at 24 months. The Apa-RP study, which met its primary endpoint, assessed high-risk localized prostate cancer patients...

Colgate Palmolive Insider Sold Shares Worth $579,696, According to a Recent SEC Filing

May 3, 2024

04:07 PM EDT, 05/03/2024 (MT Newswires) -- John P Bilbrey, Director, on May 01, 2024, sold 6,329 shares in Colgate Palmolive ( CL ) for $579,696. Following the Form 4 filing with the SEC, Bilbrey has control over a total of 34,955 shares of the company, with 30,236 shares held directly and 4,719 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/21665/000122520824005537/xslF345X03/doc4.xml ...

Colgate Palmolive Insider Sold Shares Worth $562,091, According to a Recent SEC Filing

May 3, 2024

04:06 PM EDT, 05/03/2024 (MT Newswires) -- Sally Massey, Chief Human Resources Officer, on May 01, 2024, sold 6,115 shares in Colgate Palmolive ( CL ) for $562,091. Following the Form 4 filing with the SEC, Massey has control over a total of 21,668 shares of the company, with 13,924 shares held directly and 7,744 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/21665/000122520824005538/xslF345X03/doc4.xml...